Skip to main
  1. Stocks
  2. NeuroPace
  3. Forecast
NPCE

NeuroPace (NPCE) Stock Forecast & Price Target

NeuroPace (NPCE) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

NeuroPace is viewed favorably because its RNS System is a differentiated, data-rich therapy that addresses a large, underpenetrated epilepsy market, with penetration still low despite over 10 years of approval history. The bullish case is supported by meaningful growth levers: 2023 growth of 44%, 2024 growth of 22%, and underlying 2025 RNS revenue growth of ~25%, alongside management’s indicated recovery to ~15% in 2027 and gross margins of 80%+. Additional upside comes from expanded indications such as IGE, pediatrics, and LGS, plus clinical catalysts and technology improvements like ECoG Assistant, remote programming, and next-generation devices that could improve adoption and support sustained profitability by end of 2027.

Bears say

NeuroPace is facing a fundamentally weaker commercial trajectory after 3Q26 sales of $23.1M fell below expectations and RNS revenue growth slowed to 1.4%, reflecting disruptions from sales leadership changes, field-team reorganization, and lost surgeon access after the SEEG transition. The company’s near-term outlook is further pressured by management’s reduced 2026 and 2027 sales estimates and lower EBITDA expectations, which underscore limited confidence in a quick recovery and suggest that execution problems may be more structural than transient. In addition, the FDA’s late July 2026 request for more evidence on the IGE PMA supplement, combined with concerns about competitive share loss to VNS and slower account recovery, leaves the stock dependent on clearer proof of durable commercial improvement.

NeuroPace (NPCE) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.

NeuroPace (NPCE) Analyst Forecast & Price Prediction

Get the latest NeuroPace (NPCE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NeuroPace (NPCE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroPace (NPCE) Forecast

Analysts have given NeuroPace (NPCE) a Buy based on their latest research and market trends.

According to 7 analysts, NeuroPace (NPCE) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroPace (NPCE)


NeuroPace (NPCE) Analyst Forecast & Price Prediction

Get the latest NeuroPace (NPCE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NeuroPace (NPCE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NPCE stock data and trends